The field of individualized medicines is rapidly growing. The N=1 Collaborative is excited to announce it will hold an evening gathering during the Oligonucleotide Therapeutic Society’s (OTS) annual conference this Fall in Barcelona, Spain (see below). We invite you to join in a discussion of where this field is today, the challenges unique to individualized medicines, and how we all need to work together to make this approach more routine. The event, sponsored by Charles River Laboratories, will be held at a restaurant close to the main OTS meeting venue on Monday, October 23rd, 7-9 pm. Join us for a panel discussion and Q&A, followed by continued conversation over tapas and cocktails! Spots are limited so RSVP now. Tickets will be provided on a first come, first served basis. We look forward to seeing many of you soon!
The field of individualized medicines is rapidly growing. The N=1 Collaborative is excited to announce it will hold an evening gathering during the Oligonucleotide Therapeutic Society’s (OTS) annual conference this Fall in Barcelona, Spain (see below). We invite you to join in a discussion of where this field is today, the challenges unique to individualized medicines, and how we all need to work together to make this approach more routine. The event, sponsored by Charles River Laboratories, will be held at a restaurant close to the main OTS meeting venue on Monday, October 23rd, 7-9 pm. Join us for a panel discussion and Q&A, followed by continued conversation over tapas and cocktails! Spots are limited so RSVP now. Tickets will be provided on a first come, first served basis. We look forward to seeing many of you soon! OTS Annual Meeting The OTS has been a key supporter of individualized, N-of-1/few medicines and they will be holding the 19th Annual Meeting of the Oligonucleotide Therapeutics Society on October 22-25, 2023 at Fira Barcelona Montjuic / Palau de Congressos. OTS Meeting Registration: Click Here Early bird reg deadline – September 22, 2023 Recent Seminars Thank you to the hundreds of N1C members who attended our Seminar Series over the past few months! Below are links to the recordings of our most recent talks. If you’re interested in presenting topics or (de-identified) cases, reach out to Stef Leonard at stefanie@n1collaborative.org.
Perspectives on Clinical Outcomes for N=1 Patients: Insights from N1C Clinical Outcomes Workgroup with Richard Finkel, MD, Director, Experimental Neuroscience Program at St. Jude Children's Research Hospital, and Emil Kakkis MD, PhD, founder and CEO at Ultragenyx
What if coding personalized ASO therapies only required the press of a button? with Vanessa Almendro, PhD, MBA, Head of Innovation, Danaher Corporation
New Business Models and Funding Strategies for Developing and Paying for Rare Diseases with Andrew Lo, PhD, Professor, MIT Sloan School of Management and co-founder, QLS Advisors LLC
Thanks to ChemGenes for sponsoring our 2023 Seminar Series.
Upcoming Seminars Our next talk in our series is listed below. All of our seminars run on Mondays, 1-2pm US ET. To join, look out for individual emails with the Zoom link.
August 28 - From Mutation to Dose-able CRISPR Medicine In 3 Months: Obstacles & Actionable Paths Forward, Featuring a Novel Framework for Affordable and Accessible Genetic Therapies with Fyodor Urnov, PhD, Professor of Molecular Therapeutics at UC Berkeley and a Scientific Director at its Innovative Genomics Institute, and Manar Zaghlula, PhD, Policy and Engagement Manager at the Innovative Genomics Institute of UC Berkeley
We Want to Hear from You! With 450 members and growing, we are eager to hear who is actively working on individualized medicines to understand the breadth of this field today and what the N1C can concretely do to help you. Please take just 1 minute to fill out this short Inquiry Form, thank you! N1C Member Highlight As efforts expand around the globe, we want to highlight our members who are dedicating themselves to opening up this new field. In this edition, we are featuring Haiyan Zhou, MD, PhD Associate Professor at University College London (UCL) in the United Kingdom.
Dr. Zhou’s research focuses on preclinical development of RNA-targeted novel therapies and translational biomedical research in rare genetic disorders. Dr. Zhou serves as the deputy theme lead of the Novel Therapy Theme in the NIHR Biomedical Research Centre at UCL Great Ormond Street Hospital, and leading the individualized RNA therapy Programme for paediatric rare diseases at the Great Ormond Street Institute of Child Health. She is the director of UCL Personalized Medicine and Novel Therapies MSc Programme, and holds the 2021 UK Harrington Rare Disease Scholar award. Dr. Zhou leads the national programme on establishing a UK Platform of Nucleic Acid Therapy (UPNAT) for rare disease, a specialist rare disease node supported by the UK Medical Research Council (MRC) and NIHR to expedite the rapid translation of nucleic acid therapy to the clinic. Dr. Zhou also leads in a number of research projects on the preclinical development of RNA therapeutics in muscular dystrophies (spinal muscular atrophy, Duchene muscular dystrophy and COL6-related congenital muscular dystrophy), neurodegenerative disorders (epilepsy and sensory neuropathy) and inborn errors of metabolism (lysine and tyrosine-related metabolic disorders). The research topics in her group include the identification of novel therapeutic targets, design of RNA-based therapeutic approaches (ASO, siRNA, microRNA, RNA/gene editing and mRNA), tissue/cell-specific delivery, validation in different model systems (cellular and animal), downstream functional assays and the eventual clinical translation.
Individualized Medicines in Publications and News
We are encouraged by the increasing participation in our Workgroups and Seminars! Thank you for playing a critical role in this movement!
- The N1C Team
The N=1 Collaborative is a non-profit organization with pending 501(c)(3) status. We serve as an independent hub for the development of individualized medicines whose mission is to make this approach safe and rapidly accessible to patients worldwide.
Contact us if you or your organization/company is interested in sponsoring the N1C.